![]() pEGFP- PDL1 |
|||
PVT10283 | Lifescience Market | 2 ug | EUR 301 |
![]() PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC402746-100 | Biotium | 100uL | EUR 233 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF640R conjugate, Concentration: 0.1mg/mL |
![]() PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC402746-500 | Biotium | 500uL | EUR 545 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF640R conjugate, Concentration: 0.1mg/mL |
![]() PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNCB2746-100 | Biotium | 100uL | EUR 233 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), Biotin conjugate, Concentration: 0.1mg/mL |
![]() PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNCB2746-500 | Biotium | 500uL | EUR 545 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), Biotin conjugate, Concentration: 0.1mg/mL |
![]() PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC552746-100 | Biotium | 100uL | EUR 233 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF555 conjugate, Concentration: 0.1mg/mL |
![]() PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC552746-500 | Biotium | 500uL | EUR 545 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF555 conjugate, Concentration: 0.1mg/mL |
![]() PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC702746-100 | Biotium | 100uL | EUR 233 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF770 conjugate, Concentration: 0.1mg/mL |
![]() PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC702746-500 | Biotium | 500uL | EUR 545 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF770 conjugate, Concentration: 0.1mg/mL |
![]() PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC432746-100 | Biotium | 100uL | EUR 233 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF543 conjugate, Concentration: 0.1mg/mL |
![]() PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC432746-500 | Biotium | 500uL | EUR 545 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF543 conjugate, Concentration: 0.1mg/mL |
![]() PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC472746-100 | Biotium | 100uL | EUR 233 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF647 conjugate, Concentration: 0.1mg/mL |
![]() PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC472746-500 | Biotium | 500uL | EUR 545 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF647 conjugate, Concentration: 0.1mg/mL |
![]() PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNCAP2746-100 | Biotium | 100uL | EUR 233 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
![]() PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNCAP2746-500 | Biotium | 500uL | EUR 545 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
![]() PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC802746-100 | Biotium | 100uL | EUR 233 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF680 conjugate, Concentration: 0.1mg/mL |
![]() PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC802746-500 | Biotium | 500uL | EUR 545 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF680 conjugate, Concentration: 0.1mg/mL |
![]() PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC682746-100 | Biotium | 100uL | EUR 233 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF568 conjugate, Concentration: 0.1mg/mL |
![]() PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC682746-500 | Biotium | 500uL | EUR 545 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF568 conjugate, Concentration: 0.1mg/mL |
![]() PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC812746-100 | Biotium | 100uL | EUR 233 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF680R conjugate, Concentration: 0.1mg/mL |
![]() PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC812746-500 | Biotium | 500uL | EUR 545 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF680R conjugate, Concentration: 0.1mg/mL |
![]() PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC882746-100 | Biotium | 100uL | EUR 233 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF488A conjugate, Concentration: 0.1mg/mL |
![]() PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC882746-500 | Biotium | 500uL | EUR 545 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF488A conjugate, Concentration: 0.1mg/mL |
![]() PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC612746-100 | Biotium | 100uL | EUR 233 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF660R conjugate, Concentration: 0.1mg/mL |
![]() PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC612746-500 | Biotium | 500uL | EUR 545 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF660R conjugate, Concentration: 0.1mg/mL |
![]() PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC942746-100 | Biotium | 100uL | EUR 233 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF594 conjugate, Concentration: 0.1mg/mL |
![]() PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC942746-500 | Biotium | 500uL | EUR 545 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF594 conjugate, Concentration: 0.1mg/mL |
![]() PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNCA2746-250 | Biotium | 250uL | EUR 394 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), APC conjugate, Concentration: 0.1mg/mL |
![]() PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNUB2746-100 | Biotium | 100uL | EUR 264 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), Concentration: 0.2mg/mL |
![]() PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNUB2746-500 | Biotium | 500uL | EUR 513 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), Concentration: 0.2mg/mL |
![]() PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNUM2746-50 | Biotium | 50uL | EUR 405 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), 1mg/mL |
![]() PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNCH2746-100 | Biotium | 100uL | EUR 233 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
![]() PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNCH2746-500 | Biotium | 500uL | EUR 545 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
![]() PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC042746-100 | Biotium | 100uL | EUR 233 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF405S conjugate, Concentration: 0.1mg/mL |
![]() PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC042746-500 | Biotium | 500uL | EUR 545 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF405S conjugate, Concentration: 0.1mg/mL |
![]() PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC052746-100 | Biotium | 100uL | EUR 233 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF405M conjugate, Concentration: 0.1mg/mL |
![]() PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC052746-500 | Biotium | 500uL | EUR 545 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF405M conjugate, Concentration: 0.1mg/mL |
![]() PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNCP2746-250 | Biotium | 250uL | EUR 394 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), PerCP conjugate, Concentration: 0.1mg/mL |
![]() PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNCR2746-250 | Biotium | 250uL | EUR 394 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), RPE conjugate, Concentration: 0.1mg/mL |
![]() Human Cancer PrimaCell15: Skin Cancer Cells |
|||
2-96038 | CHI Scientific | 1 Kit | Ask for price |
![]() h CD274 (PDL1) (6His) inducible lentiviral particles |
|||
LVP1077 | GenTarget | 1x107 IFU/ml x 200ul | EUR 451 |
Description: Pre-made over-expression lentivirus for expressing C-terminal His-Taggedhuman target: CD274 (6His) (human CD274 molecule), [alternative names: B7-H; B7H1; PD-L1; PDCD1L1; PDCD1LG1; PDL1]. The sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_014143.3. It contains a RFP-Blasticidin dual selection marker. |
![]() Human Cancer Antigen CA125 (Ovarian Cancer) Protein |
|||
abx061590-100kU | Abbexa | 100 kU | EUR 1205 |
![]() Human Cancer PrimaCell15: Skin Cancer Cells Growth Medium |
|||
9-46038 | CHI Scientific | 5 x 100 ml | Ask for price |
![]() Bladder Cancer Exosome |
|||
P141-BL | 101Bio | - | Ask for price |
![]() Breast Cancer Exosome |
|||
P141-BR | 101Bio | - | Ask for price |
![]() Colorectal Cancer Exosome |
|||
P141-CO | 101Bio | - | Ask for price |
![]() Kidney Cancer Exosome |
|||
P141-KN | 101Bio | - | Ask for price |
![]() Lung Cancer Exosome |
|||
P141-LG | 101Bio | - | Ask for price |
![]() Liver Cancer Exosome |
|||
P141-LV | 101Bio | - | Ask for price |
![]() Nasopharyngeal Cancer Exosome |
|||
P141-NA | 101Bio | - | Ask for price |
![]() Prostate Cancer Exosome |
|||
P141-PR | 101Bio | - | Ask for price |
![]() Thyroid Cancer Exosome |
|||
P141-TH | 101Bio | - | Ask for price |
![]() h CD274 (PDL1) (6His, GFP-Puro) inducible lentiviral particles |
|||
LVP1077-GP | GenTarget | 1x107 IFU/ml x 200ul | EUR 451 |
Description: Pre-made over-expression lentivirus for expressing C-terminal His-Taggedhuman target: CD274 (6His) (human CD274 molecule), [alternative names: B7-H; B7H1; PD-L1; PDCD1L1; PDCD1LG1; PDL1]. The sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_014143.3. It contains a GFP-Puromycin dual selection marker. |
![]() Human Cancer Tissue Preparation Buffer 15: Skin Cancer Cells |
|||
9-80038 | CHI Scientific | 1 x 100 ml | Ask for price |
![]() Melanoma (skin cancer) Exosome |
|||
P141-MN | 101Bio | - | Ask for price |